A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

被引：160

作者：

Comabella, M. ^{[1
]}

Luenemann, J. D. ^{[2
]}

Rio, J. ^{[1
]}

Sanchez, A. ^{[3
]}

Lopez, C. ^{[1
]}

Julia, E. ^{[1
]}

Fernandez, M. ^{[1
]}

Nonell, L. ^{[1
]}

Camina-Tato, M. ^{[1
]}

Deisenhammer, F. ^{[4
]}

Caballero, E. ^{[5
]}

Tortola, M. T. ^{[5
]}

Prinz, M. ^{[6
]}

Montalban, X. ^{[1
]}

Martin, R. ^{[7
]}

机构：

[1] Univ Autonoma Barcelona, Unitat Neuroimmunol Clin, CEM Cat,Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya,Dept Med, Barcelona 08035, Spain

[2] Rockefeller Univ, Lab Viral Immunobiol, Christopher H Browne Ctr Immunol & Immune Dis, New York, NY 10021 USA

[3] Univ Barcelona, Fac Biol, Dept Estadist, E-08028 Barcelona, Spain

[4] Innsbruck Med Univ, Dept Clin Neurol, A-6020 Innsbruck, Austria

[5] HUVH, Microbiol Serv, Barcelona 08035, Spain

[6] Univ Freiburg, Inst Neuropathol, D-79106 Freiburg, Germany

[7] Icrea, Barcelona 08035, Spain

来源：

BRAIN | 2009年 / 132卷

关键词：

multiple sclerosis; monocytes; gene-expression signature; interferon-beta; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PERIPHERAL-BLOOD CELLS; TIME QUANTITATIVE PCR; DENDRITIC CELLS; GENE-EXPRESSION; IFN-BETA; IMMUNE-RESPONSE; VIRAL-INFECTION; DOUBLE-BLIND; T-CELLS;

D O I：

10.1093/brain/awp228

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The effect of interferon-beta in multiple sclerosis is modest and many patients do not respond to treatment. To date, no single biomarker reliably correlates with responsiveness to interferon-beta in multiple sclerosis. In the present study, genome-wide expression profiling was performed in peripheral blood mononuclear cells from 47 multiple sclerosis patients treated with interferon-beta for a minimum of 2 years and classified as responders and non-responders based on clinical criteria. A validation cohort of 30 multiple sclerosis patients was included in the study to replicate gene-expression findings. Before treatment, interferon-beta responders and non-responders were characterized by differential expression of type I interferon-induced genes with overexpression of the type interferon-induced genes in non-responders. Upon treatment the expression of these genes remained unaltered in non-responders, but was strongly upregulated in responders. Functional experiments showed a selective increase in phosphorylated STAT1 levels and interferon receptor 1 expression in monocytes of non-responders at baseline. When dissecting this type I interferon signature further, interferon-beta non-responders were characterized by increased monocyte type I interferon secretion upon innate immune stimuli via toll-like receptor 4, by increased endogenous production of type I interferon, and by an elevated activation status of myeloid dendritic cells. These findings indicate that perturbations of the type I interferon signalling pathway in monocytes are related to lack of response to interferon-beta, and type I interferon-regulated genes may be used as response markers in interferon-beta treatment.

引用

页码：3353 / 3365

页数：13

共 44 条

[31] Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system [J].

Prinz, Marco ;

Schmidt, Hauke ;

Mildner, Alexander ;

Knobeloch, Klaus-Peter ;

Hanisch, Uwe-Karsten ;

Raasch, Jenni ;

Merkler, Doron ;

Detje, Claudia ;

Gutcher, Ilona ;

Mages, Joerg ;

Lang, Roland ;

Martin, Roland ;

Gold, Ralf ;

Becher, Burkhard ;

Bruck, Wolfgang ;

Kalinke, Ulrich .

IMMUNITY, 2008, 28 (05) :675-686

[32]

Radvanyi LG, 1999, SCAND J IMMUNOL, V50, P499

[33] Relationship between MRI lesion activity and response to IFN-β in relapsing-remitting multiple sclerosis patients [J].

Rio, J. ;

Rovira, A. ;

Tintore, M. ;

Huerga, E. ;

Nos, C. ;

Tellez, N. ;

Tur, C. ;

Comabella, M. ;

Montalban, X. .

MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (04) :479-484

[34] Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients [J].

Río, J ;

Nos, C ;

Tintoré, M ;

Téllez, N ;

Galán, I ;

Pelayo, R ;

Comabella, M ;

Montalban, X .

ANNALS OF NEUROLOGY, 2006, 59 (02) :344-352

[35] Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β:: Implications for clinical trials [J].

Río, J ;

Nos, C ;

Tintoré, M ;

Borrás, C ;

Galán, I ;

Combella, M ;

Montalban, X .

ANNALS OF NEUROLOGY, 2002, 52 (04) :400-406

[36] TAM receptors are pleiotropic inhibitors of the innate immune response [J].

Rothlin, Carla V. ;

Ghosh, Sourav ;

Zuniga, Elina I. ;

Oldstone, Michael B. A. ;

Lemke, Greg .

CELL, 2007, 131 (06) :1124-1136

[37] Sensitization to TLR7 agonist in IFN-β-preactivated dendritic cells [J].

Severa, Martina ;

Remoli, Maria Elena ;

Giacomini, Elena ;

Annibali, Viviana ;

Gafa, Valerie ;

Lande, Roberto ;

Tomai, Mark ;

Salvetti, Marco ;

Coccia, Eliana M. .

JOURNAL OF IMMUNOLOGY, 2007, 178 (10) :6208-6216

[38] Differential responsiveness to IFN-α and IFN-β of human mature DC through modulation of IFNAR expression [J].

Severa, Martina ;

Remoli, Maria Elena ;

Giacomini, Elena ;

Ragimbeau, Josiane ;

Lande, Roberto ;

Uze, Gilles ;

Pellegrini, Sandra ;

Coccia, Eliana M. .

JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 79 (06) :1286-1294

[39] Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS [J].

Soilu-Hänninen, M ;

Laaksonen, M ;

Hänninen, A ;

Erälinna, JP ;

Panelius, M .

JOURNAL OF NEUROIMMUNOLOGY, 2005, 167 (1-2) :175-182

[40] Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases [J].

Stewart, TA .

CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (02) :139-154

← 1 2 3 4 5 →